



National Niemann-Pick Disease Foundation, Inc.
401 Madison Avenue, Suite B; Post Office Box 49
Fort Atkinson, WI 53538-0049
Tele: 920-563-0930; Fax: 920-563-0931
Web Site: www.nnpdf.org; E-mail: nnpdf@nnpdf.org

August 17, 2015

Dear NNPFD ASMD Patient and Family Community,

The National Niemann-Pick Disease Foundation (NNPDF) is pleased to advise our Niemann-Pick Disease Type A/B & Type B (aka: Acid Sphingomyelinase Deficiency ~ ASMD) Disease patient's & family community that Genzyme, A Sanofi Company, has received FDA authorization to begin recruiting for the pediatric clinical trial of Enzyme Replacement Therapy (ERT) for pediatric patients in the United States.

The ERT pediatric clinical trial site for the United States has been established at Mount Sinai Hospital in New York under the direction of Dr. Melissa Wasserstein and will begin recruiting for pediatric patients diagnosed with ASMD (NPD Type B) within the age ranges listed below:

- Birth to under 6 years of age
- 6 years of age to under 12 years of age
- 12 years of age to under 18 years of age

The official name of this trial is: "Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients under 18 Years of Age with Acid Sphingomyelinase Deficiency (ASCEND-Peds)" and has been assigned the clinical trial number of: NCT02292654. To learn more about this trial, please consult with your physician and refer to the web site titled: <https://clinicaltrials.gov/>

This therapy has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration is a Phase 1/2 trial which is a multi-national, multi-center, open label, trial for pediatric patients with ASMD. All of this information and more is addressed in the official Genzyme press release you will find enclosed.

As we look to the future, Genzyme is also preparing for enrollment to begin in a Phase 2/3 clinical trial involving adult patients with ASMD sometime during the second half of 2015. As soon as more information associated with the adult clinical trial and further updates to the pediatric clinical trials are made available to the NNPFD we will be certain to share this information with our ASMD patient and family membership community.

The foundation is also pleased to announce to our Niemann-Pick Type B (ASMD) patient community a new “Qualitative Research Phase” titled: Patient Reported Outcome (PRO) sponsored by Genzyme. Patient-Reported-Outcome (PRO) instruments are measures self-reported by patients, about disease symptoms and impact, as well as impact of treatment.

Please review the enclosed document titled: “ASMD/NPB Patient Reported Outcome (PRO) Development ~ Qualitative Research Phase”, which further details the patient interview study and the essential component this information will play in support of the entire ASMD community and the upcoming clinical trial efforts.

WHO CAN PARTICIPATE

This PRO Qualitative Research Phase includes adults with ASMD, children older than 7 years of age, as well as parents/caregivers of children with ASMD/NPB. Your participation in the interviews for PRO measure development study does not prevent you from, or provide preference for, participating in any current or future clinical studies mentioned earlier.

As always, should you have any questions regarding this mailing and announcements ~ please feel free to contact the NNPfD Central Offices.

We WILL Persevere in our Quest for a Cure!

Sincerely,



Nadine M. Hill
Executive Director
National Niemann-Pick Disease Foundation
nhill@nnpdf.org

NOTE: None of the above signatories engage in the practice of medicine, nor do we claim to be a medical authority or claim to have medical knowledge. This document is designed to be an educational service and is not meant to provide diagnostic or treatment advice. Information contained or suggested on this document does not constitute medical advice. For all information related to care, medication or treatment, it is recommended that you consult a physician to determine if the information presented is applicable.

It should also be noted that choosing to participate in a clinical study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff indicated on Clinicaltrials.gov once the trial begins to recruit patients. For general information about taking part in a clinical trial please see: The US Government Web Page Titled: Learn About Clinical Studies via this link: <https://www.clinicaltrials.gov/ct2/about-studies/learn>



Published on Genzyme Corporation Online Newsroom (<http://news.genzyme.com>) on 6/15/15 8:00 am EDT

Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients

Release Date:

Monday, June 15, 2015 8:00 am EDT

Terms:

Dateline City:

CAMBRIDGE, Mass.

First patient dosed with investigational enzyme replacement therapy designed to treat the nonneurological manifestations of ASMD which characterize Niemann-Pick disease type B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that the first pediatric patient has begun treatment in a Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa. Olipudase alfa is an enzyme replacement therapy being studied for the treatment of nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B, as opposed to type A, which is characterized by neurological involvement. ASMD is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase (ASM) resulting in toxic accumulation of sphingomyelin. There are currently no approved treatment options for patients with Niemann-Pick disease type B.

The Phase 1/2 trial is a multi-national, multi-center, open label, ascending dose trial to evaluate the safety, tolerability and pharmacokinetics of olipudase alfa administered intravenously once every 2 weeks for 52 weeks in pediatric patients with ASMD. Twelve pediatric patients will be enrolled into 3 age cohorts: an adolescent cohort (12 to <18 years of age); a child cohort (6 to <12 years of age); and an infant/early child cohort (birth to <6 years of age). The primary objective of the Phase 1/2 trial is to assess the safety and tolerability of olipudase alfa. Upon completion of the 52-week trial, patients will have the option to enroll into an extension study. Genzyme is preparing for enrollment to begin in a Phase 2/3 trial involving adult patients with ASMD in the second half of 2015. For more information please visit <http://clinicaltrials.gov>.

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. Breakthrough Therapy designation is intended to expedite the development and review of investigational new drugs that target serious or life-threatening conditions. The criteria for granting Breakthrough Therapy designation are preliminary clinical evidence of substantial improvement on a clinically significant endpoint over available therapies. The Breakthrough Therapy designation is distinct from the FDA's other mechanisms to expedite drug development and review, and will allow for a close collaboration between Genzyme and the FDA on the olipudase alfa development program.

"With start of clinical studies both in pediatric and adult patients just a few months apart, we are confirming our commitment to the Niemann Pick disease patient community to advance the development of this novel therapy as quickly as possible and for both patient populations," said Head of the Sanofi Genzyme R&D Center, Jim Burns, Ph.D. "We are very grateful to the patients for their engagement and their support in advancing this exciting program."

About ASMD (Niemann-Pick Disease)

Traditionally called Niemann-Pick disease types A and B (NPD A and NPD B), Acid Sphingomyelinase Deficiency (ASMD) is one of a group of lysosomal storage diseases that affect the metabolism and that are caused by genetic mutations. ASMD is caused by the deficiency of a specific enzyme, acid sphingomyelinase (ASM). This enzyme is found in special compartments within cells called lysosomes and is required to metabolize a lipid called sphingomyelin. If ASM is absent or not functioning properly, sphingomyelin cannot be metabolized properly and is accumulated within the cell, eventually causing cell death and the malfunction of major organ systems. Niemann-Pick A and Niemann-Pick B are both caused by the same enzymatic deficiency and there is growing evidence that the two forms represent opposite ends of a continuum.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.

Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT:SAN) and in New York (NYSE:SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Language:

English

Contact:

Genzyme Media Relations
Lori Gorski +1 617-768-9344
lori.gorski@genzyme.com

or
Sanofi Investor Relations
Sébastien Martel, +33 (0) 1 53 77 45 43
ir@sanofi.com

Ticker Slug:

Ticker:
SNY

Exchange:
NYSE

ISIN:
US80105N1054

Ticker:
SAN

Exchange:
BOURSE

ISIN:
FR0000120578

Source URL: <http://news.genzyme.com/press-release/genzyme-initiates-phase-12-clinical-trial-evaluate-olipudase-alfa-pediatric-patients>

Acid Sphingomyelinase Deficiency (ASMD)/Niemann-Pick Disease Type B (NPD B) Patient-Reported Outcome (PRO) Development

Qualitative Research Phase

Patient Interview Study Information

ABOUT PRO

Patient-Reported-Outcome (PRO) instruments are measures self-reported by patients, about disease symptoms and impact, as well as impact of treatment. When evaluating disease management, quality of care and effectiveness of new treatments, PROs are very important in understanding what is important and meaningful from patients' perspectives, and how health care interventions can be used to improve patients' health and health-related quality of life. PROs are increasingly being incorporated into clinical programs, medical practice and in observational research, to evaluate and monitor the impact of medical treatments and health interventions and thus deliver care that is most important and valuable to patients.

AIM OF PRO INITIATIVE

In the light of its commitment to patient-centricity and with the aim to continuously support the patients with Acid Sphingomyelinase Deficiency (ASMD), Genzyme a Sanofi Company has launched an initiative to develop a disease-specific ASMD/ Niemann-Pick Disease Type B (NPD B) PRO instrument. Input from the patient community is a central part of PRO development. In addition to clinical expert interviews and evidence reviews, this research initiative involves also in-depth interviews with patients with ASMD and/or their parents/ caregivers. The objective of interviews is to hear patients' and caregivers' opinion and perspectives, about the experience with symptoms of ASMD and about the impacts and burden that the disease has on their lives.

VALUE OF NEW PRO MEASURE

The newly developed PRO assessment tool will be available for use widely in various contexts and settings, including clinical research and medical practices. It will provide a comprehensive and standard tool to health care providers to measure severity, progression and overall burden of disease in patients with ASMD, as well as allow assessing and improving quality and effectiveness of care and interventions in a wider sense. This new PRO measure can also be used by researchers and other parties to understand disease impact, severity and progression of disease, as well as the value of treatments and interventions.

PATIENT INTERVIEWS

Patient input is an essential component of this initiative. Interviews will involve a one-hour discussion by an experienced scientist interviewer with patients and/or parents/caregivers. Participants will be asked questions about disease symptoms, disease impact and general questions about living with ASMD. Interviews will take place via telephone or face-to-face at a location that is convenient for participants. Participation in the interviews is absolutely voluntary and patients and/or parents/caregivers may withdraw their participation at any time.

WHO CAN PARTICIPATE

This research includes adults with ASMD, children older than 7 years of age, as well as parents/ caregivers of children with ASMD/NPD B. Your participation in the interviews for PRO measure development study does not prevent you from, or provide preference for, participating in any current or future clinical studies.

HOW TO PARTICIPATE

The interviews will be conducted by researchers from a consulting company - Evidera, on behalf of Genzyme. Evidera is required by law to ensure participants' privacy and to maintain the confidentiality of all patient level data and materials. If you are interested in learning more about this opportunity or participating in these interviews, please reach out to Evidera at the following numbers:

- US/Canada toll free number:
1-800-257-3157
- UK toll free number:
0800-088-5390
- You can also contact the Evidera research team at the following e-mail address:
ASMDPro@evidera.com.

You may be enrolled in the study, once your eligibility is established.

National Niemann-Pick Disease Foundation is not involved in this study and will not have access to any of interview responses.